Compare RYTM & ONTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYTM | ONTO |
|---|---|---|
| Founded | 2008 | 1940 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 10.9B |
| IPO Year | 2017 | 1995 |
| Metric | RYTM | ONTO |
|---|---|---|
| Price | $92.47 | $183.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | $129.93 | ★ $229.38 |
| AVG Volume (30 Days) | 709.0K | ★ 862.9K |
| Earning Date | 05-25-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.34 | N/A |
| EPS | N/A | ★ 2.78 |
| Revenue | N/A | N/A |
| Revenue This Year | $57.46 | $26.63 |
| Revenue Next Year | $85.60 | $16.26 |
| P/E Ratio | ★ N/A | $66.18 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.91 | $89.40 |
| 52 Week High | $122.20 | $232.49 |
| Indicator | RYTM | ONTO |
|---|---|---|
| Relative Strength Index (RSI) | 43.88 | 38.48 |
| Support Level | $85.59 | $180.18 |
| Resistance Level | $96.92 | $229.81 |
| Average True Range (ATR) | 4.88 | 10.67 |
| MACD | -0.24 | -4.13 |
| Stochastic Oscillator | 31.57 | 14.67 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Onto Innovation Inc is engaged in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The Company and its subsidiaries currently operate in a single operating segment. The company mainly operates in the United States, Southeast Asia, China, Japan, and Europe, with Taiwan and South Korea the sources of total revenue.